Lactose Intolerance

Lactose Intolerance: A Nutritional and Natural-Health Reference

1. Definition and Overview

Lactose intolerance (LI) is defined as the onset of abdominal symptoms such as abdominal pain, bloating, and diarrhoea after lactose ingestion by an individual with lactose malabsorption. It is important to distinguish this clinical syndrome from the underlying enzymatic condition. Lactose malabsorption (LM) refers to any cause of failure to digest and/or absorb lactose in the small intestine, including primary genetic and secondary lactase deficiency due to infection or other conditions that affect the mucosal integrity of the small bowel. Although often associated with lactose malabsorption, the two terms are not synonymous.

Lactose is a disaccharide and the primary sugar in human breast milk; it is hydrolyzed into glucose and galactose by the enzyme lactase, located in the small intestinal border. Dietary lactose must be hydrolyzed to a monosaccharide in order to be absorbed by the small intestinal mucosa; a deficiency of intestinal lactase prevents hydrolysis of ingested lactose.

2. Pathophysiology and Body Systems Involved

In healthy individuals, dietary lactose is hydrolyzed into glucose and galactose by lactase, an enzyme located in the brush border of the small intestine. Deficiency of this enzyme, whether from primary genetic factors or secondary to intestinal injury, results in incomplete lactose digestion, leading to fermentation by colonic bacteria and the development of characteristic symptoms such as bloating, diarrhea, and abdominal discomfort.

If an adult consumes more lactose than their body can break down with the available lactase, some lactose is left over in the small intestine. It passes on into the large intestine, where it is digested by intestinal bacteria through fermentation. As a result, more gases like carbon dioxide (CO₂) and hydrogen, and other byproducts like fluids and fatty acids are produced in the bowel, causing the typical symptoms of lactose intolerance.

The primary organ systems involved are:

• Small intestine: Lactase deficiency is the failure to express the enzyme that hydrolyses lactose into galactose and glucose in the small intestine.
• Large intestine (colon): Lactase non-persistence results in lactose malabsorption, which allows undigested lactose to move into the colon. Fermentation of lactose in the colon can produce carbon dioxide, hydrogen gas, methane, and short-chain fatty acids, leading to a range of abdominal and bowel-related symptoms including abdominal pain, cramping, discomfort, bloating, distension, flatulence, increased stool frequency, and loose or watery stools.
• Nervous/visceral sensitivity axis: Many patients with functional GI disorders have psychological comorbidity and are hypersensitive to dietary and physical stimuli. Further work demonstrated that anxiety, visceral hypersensitivity, and high levels of gas production on breath tests all increased the severity of abdominal symptoms after ingestion of lactose. Moreover, mucosal biopsies showed increased numbers of mast cells and intraepithelial lymphocytes in lactose-sensitive patients, and the release of inflammatory cytokines after lactose intake was higher in this group than controls.

3. Clinical Presentation

The clinical symptoms of lactose intolerance include nausea, vomiting, abdominal distension, cramps, flatulence, flatus, diarrhea, and abdominal pain. The severity and onset of symptoms are not uniform. Recent studies show that the risk of symptoms after lactose ingestion depends on the dose of lactose, lactase expression, intestinal flora, and sensitivity of the gastrointestinal tract. Even patients with lactase deficiency can often tolerate up to 20 g lactose.

4. Types and Classification

Lactase deficiency is classified into four types: primary (late-onset), secondary (acquired), developmental, and congenital.

4.1 Primary (Adult-Onset) Lactase Non-Persistence

Primary lactose intolerance occurs as the amount of lactase declines as people grow up. The production of the lactase enzyme typically decreases after weaning in most populations. This genetically programmed reduction is referred to as lactase non-persistence. Approximately 70% of the world's population has primary lactase deficiency. The percentage varies according to ethnicity and is related to the use of dairy products in the diet, resulting in genetic selection of individuals with the ability to digest lactose.

4.2 Secondary (Acquired) Lactase Deficiency

Secondary lactase deficiency is lactase deficiency that results from small bowel injury, such as acute gastroenteritis, persistent diarrhea, small bowel overgrowth, cancer chemotherapy, or other causes of injury to the small intestinal mucosa, and can present at any age but is more common in infancy. Secondary lactose intolerance is due to injury to the small intestine. Such injury could be the result of infection, celiac disease, inflammatory bowel disease, or other diseases. Secondary deficiency is typically reversible following resolution of the underlying intestinal injury.

4.3 Congenital Lactase Deficiency

Congenital lactase deficiency (CLD) is a severe autosomal recessive genetic disorder that affects the functional capacity of the intestinal protein lactase-phlorizin hydrolase (LPH). This disorder is diagnosed already during the first few days of the newborn's life due to the inability to digest lactose. The symptoms include severe osmotic watery diarrhea. CLD is associated with mutations in the translated region of the LPH gene that elicit loss-of-function of LPH. Congenital lactose malabsorption is a very rare condition that occurs in the first few days of life and requires infant formula that is totally free of lactose; affected populations are mainly in Finland and Western Russia.

4.4 Developmental Lactase Deficiency

Developmental lactose intolerance may occur in premature babies and usually improves over a short period of time. Developmental lactase deficiency, in which there is a relative lactase deficiency, occurs in preterm neonates younger than 34 weeks' gestation.

5. Contributing and Associated Factors

5.1 Genetics

Genetic factors contribute significantly, with specific single-nucleotide polymorphisms (SNPs) associated with lactose intolerance. Among Indo-Europeans, the C/T 13910 (C>T) polymorphism plays a key role: the TT genotype is associated with lactase persistence, the C/T genotype with partial deficiency, and the CC genotype with complete deficiency. The frequency of lactase persistence, which allows lactose tolerance, varies enormously worldwide, with the highest prevalence in Northwestern Europe, declining across southern Europe and the Middle East, and being low in Asia and most of Africa, although it is common in pastoralist populations from Africa.

5.2 Ethnicity and Geography

Persons of all races are affected by lactose intolerance, with a higher prevalence among Asian, African, and South American persons. The prevalence of lactase non-persistence varies markedly depending on geographic region and ancestry, with higher persistence observed in Northern European populations and reduced persistence in many Asian, African, and Indigenous American groups.

5.3 Age

Enzyme levels are the highest shortly after birth and decline with aging, despite continued intake of lactose. The reduction of lactase production starts typically in late childhood or early adulthood, and prevalence increases with age.

5.4 Underlying Gastrointestinal Disease

Lactose intolerance can also develop due to other health problems, known as acquired or secondary lactose intolerance, including chronic inflammation (like in Crohn's disease) or injury to the lining of the intestine. It happens when the small intestine starts producing too little lactase because the lining of the intestine has been damaged.

5.5 Irritable Bowel Syndrome (IBS) and Visceral Hypersensitivity

The threshold for dietary lactose tolerance is dependent on several factors including the dose consumed, residual lactase expression, ingestion with other dietary components, gut-transit time, small bowel bacterial overgrowth, and the composition of the enteric microbiome (e.g., high vs. low fermenters, hydrogen vs. methane producers). Patients with irritable bowel syndrome are at particular risk of both self-reporting dairy intolerance and experiencing symptoms after lactose and FODMAP ingestion. Visceral hypersensitivity is present in at least half of patients with irritable bowel syndrome (IBS), and this group requires not only restriction of lactose intake but also a low-FODMAP diet to improve gastrointestinal complaints.

5.6 Gut Microbiome

Higher levels of beneficial gut bacteria called Bifidobacteria are associated with the human lactase nonpersister genotype, which typically confers lactose intolerance, in several different human populations. Research provides evidence that specific gut symptoms experienced by lactose-intolerant patients might be the result of Bifidobacterium abundance in the gut, rather than a direct effect of lactose intake. This work supports initial reports where metabolic products of lactose-fermenting bacteria may be related to lactose intolerance symptom occurrence.

6. Nutritional Consequences

6.1 Calcium

Lactose intolerance may predispose individuals to low calcium intake as the number of lactose-free, calcium-rich food sources is limited. Based on the available evidence, neither dietary lactose nor lactase deficiency has a significant impact on calcium absorption in adult humans. However, lactose intolerance may lead to reduced bone density and fragility fractures when accompanied by decreased intake or avoidance of dairy.

6.2 Vitamin D and Other Bone-Related Nutrients

In addition to calcium, vitamin D, vitamin A, potassium, zinc, and magnesium in dairy products are also important nutrients in bone formation. Cow's milk is one of the major sources of calcium and several other vitamins and minerals. A complete exclusion of dairy products may favor the development of bone diseases such as osteopenia and osteoporosis. Therefore, the dietetic approach has a crucial role in the management of lactose intolerance.

6.3 Skeletal and Bone Health in Children

Children and adolescents with maldigestion should especially be encouraged to maintain dairy food intake to meet the needs of skeletal growth and to optimize peak bone mass, most of which is attained before the age of 16. Children who avoid milk ingest less-than-recommended amounts of calcium and may be at increased risk for deficient bone accretion. Cases of severe rickets due to vitamin D deficiency have been described in children who do not consume dairy.

6.4 Public Health Guidance

Given the availability of simple dietary approaches to building lactose tolerance and the nutritional deficiencies associated with dairy avoidance, multiple public health organizations recommend that all individuals—including those who are lactose intolerant—consume three servings of dairy per day to ensure adequate nutrient intakes and optimal bone health. The European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition, and Allergies also emphasized the need for objective testing before recommending a low-lactose diet and the intake of lactose-reduced and lactose-free products to avoid calcium, vitamin D, and riboflavin deficiencies.

7. Natural Ingredients and Approaches: Traditional Use and Scientific Evidence

7.1 Lactase Enzyme (Exogenous Supplementation)

Traditional Use: Exogenous lactase, derived from fungal sources (typically Aspergillus oryzae or Kluyveromyces lactis), has been used for several decades as an over-the-counter supplement, taken orally with dairy foods to pre-digest lactose before it reaches the colon.

Scientific Evidence: Research suggests that those with lactose intolerance can benefit from use of supplementary lactase enzymes with lactose-rich foods to manage symptoms associated with lactose maldigestion. Studies conducted among both adults and children show the efficacy of exogenous lactase in reduction of bloating, abdominal pain, and gas. Lactase supplements are considered among the most effective natural treatments, allowing individuals to digest lactose more easily. The evidence base is considered relatively robust, though individual variability in response exists.

7.2 Probiotics

Traditional Use: Fermented dairy foods containing live bacterial cultures have been consumed for millennia across diverse cultures — including yogurt in the Middle East and Central Asia, kefir in Eastern Europe, and cultured milks in Africa and South Asia — specifically because they were observed to be better tolerated than fresh milk. These practices predate any formal understanding of microbiology.

Scientific Evidence: Accumulating evidence has shown that probiotic bacteria in fermented and unfermented milk products can be used to alleviate the clinical symptoms of lactose intolerance. In one systematic review, the effectiveness of probiotics was evaluated using 15 randomized double-blind studies, examining eight probiotic strains with the greatest number of proven benefits. Results showed varying degrees of efficacy but an overall positive relationship between probiotics and lactose intolerance.

However, the evidence is not uniformly positive. In at least one earlier systematic review, probiotic supplementation in general did not alleviate the symptoms and signs of lactose intolerance in adults, though some evidence suggested that specific strains, concentrations, and preparations are effective.

More recent reviews confirm strain specificity is critical. The probiotics Limosilactobacillus reuteri DSM 17938 and Lactobacillus acidophilus DDS-1 showed the best results in the management of lactose intolerance symptoms. The prebiotic GOS (RP-G28) appeared to be more efficient in reducing post-treatment symptoms. However, evidence regarding the use of probiotics for the management of lactose intolerance is considerably scarce, and for prebiotics, data are limited.

The proposed mechanisms are multifactorial. By reducing colonic lactose availability and altering microbial metabolism, probiotics can modulate fermentation outputs of H₂, CO₂, CH₄, H₂S, and short-chain fatty acids (SCFAs), and may suppress gas-producing microbes through competitive interactions. Probiotics may also modulate the colonic microbiota by increasing lactose-utilizing taxa and overall beta-galactosidase activity, while typically remaining transient rather than permanently colonizing.

7.3 Yogurt and Fermented Dairy

Traditional Use: Traditionally, lactose-intolerant populations have consumed yogurt without experiencing symptoms. Fermented dairy products, such as yogurt and hard cheeses, have long been employed as a strategy for overcoming lactose intolerance because they contain lactose that is partially digested by live bacteria.

Scientific Evidence: The lactose in yogurt is digested more efficiently than other dairy sources of lactose because the bacteria inherent in yogurt assist with its digestion. The bacterial lactase survives the acidic conditions of the stomach, apparently being physically protected within the bacterial cells and facilitated by the buffering capacity of yogurt.

Yogurt with sufficient numbers of S. thermophilus and L. bulgaricus (as is the case in most commercial yogurts) is very well tolerated by lactose maldigesters, because it is effectively analogous to taking an enzyme supplement with a dairy food.

According to an expert panel, there is "strong evidence for the biological plausibility of the effect," and sufficient proof that a cause-effect association exists between yogurt consumption and improved lactose digestion to support a health claim for yogurts containing at least 10⁸ colony-forming units (CFU) per gram.

Fermented dairy, especially yogurt with live cultures, can improve lactose digestion compared with unfermented milk because starter cultures provide beta-galactosidase activity and slow gastric emptying, allowing many lactose-intolerant individuals to tolerate modest lactose loads. The evidence strength for yogurt specifically is considered strong and is reflected in regulatory health claims in some jurisdictions.

7.4 Galacto-Oligosaccharides (GOS) as Prebiotics

Traditional Use: GOS occur naturally in human breast milk and in small amounts in cow's milk, but supplemental GOS preparations are an entirely modern product with no historical traditional use per se.

Scientific Evidence: Galacto-oligosaccharides (GOS) are prebiotics that have been shown to alleviate symptoms of lactose intolerance and to modulate the intestinal microbiota, promoting the growth of beneficial microorganisms. The prebiotic GOS compound RP-G28 has been the focus of controlled trials. The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial, in which 377 patients with lactose intolerance were randomized to one of two doses or placebo for 30 days. Adaptation of colon bacteria to effectively metabolize lactose was a proposed mechanism. Efficacy trends and favorable safety/tolerability findings suggest that RP-G28 appears to be a potentially useful approach for improving lactose digestion and lactose intolerance symptoms, with concurrent reduction in abdominal pain and improved overall tolerance.

Altering the gut microbiota could be a long-term strategy to manage lactose intolerance. Researchers have reviewed evidence showing that feeding Bifidobacterium and/or galacto-oligosaccharides can modify the colonic microflora and alter the fermentation of undigested lactose. However, while pure galacto-oligosaccharides have shown efficacy in alleviating symptoms associated with lactose intolerance, variability in response to GOS has been reported. Overall, evidence is promising but still emerging, and larger, more standardized trials are needed.

7.5 Peppermint (Mentha × piperita)

Traditional Use: Peppermint has been used for centuries in European and North American herbal traditions as a carminative and antispasmodic for digestive complaints including bloating, cramping, and nausea. It is consumed as a tea or as enteric-coated oil capsules. Its use for digestive complaints is documented in numerous traditional materia medica.

Scientific Evidence (general digestive symptoms): Peppermint oil affects esophageal, gastric, small bowel, gallbladder, and colonic physiology primarily as a function of its spasmolytic properties, with such effects seen throughout the gastrointestinal tract. Placebo-controlled studies support its use in irritable bowel syndrome, functional dyspepsia, childhood functional abdominal pain, and postoperative nausea, though significant trial heterogeneity in terms of peppermint oil dose and formulation exists.

In the context of IBS — a condition that frequently overlaps with lactose intolerance — twelve randomized trials with 835 patients were included in one meta-analysis, showing that for global symptom improvement, the risk ratio for peppermint oil versus placebo was 2.39 (95% CI: 1.93, 2.97).

Limitation: Peppermint has not been studied specifically as a remedy for lactose intolerance per se. Its evidence base applies to overlapping functional gastrointestinal symptoms (cramping, bloating, spasm) that occur in both IBS and lactose intolerance, but direct evidence of peppermint modifying lactose digestion or lactase activity is absent. Evidence strength for symptom relief is moderate-to-good for IBS; for lactose intolerance specifically, evidence is indirect and limited.

7.6 Ginger (Zingiber officinale)

Traditional Use: Ginger root has been used for thousands of years in Ayurvedic, Traditional Chinese Medicine, and other Asian traditions to treat nausea, bloating, and general digestive discomfort. In Ayurveda, it is considered a digestive stimulant ("Agni" enhancer). It is prepared as tea, decoction, or taken as fresh or dried root.

Scientific Evidence (general digestive symptoms): Studies have shown that ginger accelerates gastric emptying and stimulates antral contractions in healthy individuals; research on patients with functional dyspepsia has shown the same results. A review of six studies found that ginger eases nausea and vomiting better than a placebo. As with peppermint, ginger's studied benefits relate to overlapping functional GI symptoms rather than to lactose digestion specifically. No clinical trials have examined ginger as a direct intervention for lactose intolerance. Evidence level: preliminary/indirect, with stronger evidence for nausea relief and gastric motility effects in unrelated conditions.

7.7 Fennel (Foeniculum vulgare)

Traditional Use: Fennel seeds have a long history of use as a carminative — a substance that disperses intestinal gas — across Mediterranean, South Asian (Ayurvedic), and Middle Eastern traditional medicine. Seeds were traditionally chewed after meals or prepared as infusions to relieve bloating and flatulence.

Scientific Evidence: Fennel's documented carminative properties are primarily attributed to its essential oil, particularly trans-anethole. However, no clinical trials have investigated fennel specifically for lactose intolerance. Its use in this context remains traditional and anecdotal. The available clinical evidence for fennel is limited to infant colic and, to a lesser extent, IBS symptoms, with study quality generally low to moderate.

8. Dietary and Lifestyle Factors

8.1 Lactose Dose and Food Matrix

The threshold for dietary lactose tolerance depends on the dose consumed, residual lactase expression, ingestion with other dietary components, gut-transit time, and small bowel bacterial overgrowth. Consuming dairy with solid food rather than alone slows gastric emptying and reduces the bolus of lactose reaching the colon, which can significantly improve tolerance.

8.2 Lactose-Reduced and Lactose-Free Products

The National Medical Academy (NMA) encouraged practitioners to educate their patients about the benefits of consuming the recommended three servings per day of dairy and to ensure patients are formally tested for lactose intolerance, as symptoms may have different origins. Commercially available lactose-reduced and lactose-free milk products allow individuals to obtain dairy's nutrient profile (calcium, protein, vitamin D, riboflavin) while minimizing digestive symptoms.

8.3 Aged and Hard Cheeses

Naturally aged hard cheeses — such as cheddar, parmesan, and Swiss-type cheeses — contain markedly lower concentrations of lactose because the lactose is converted to lactic acid during the fermentation and aging process. These are generally tolerated by many lactose-intolerant individuals and represent a practical source of calcium.

8.4 Non-Dairy Calcium Sources

In addition to calcium, vitamin D, vitamin A, potassium, zinc, and magnesium in dairy products are also important for bone formation. A review consisting of both randomized and observational studies highlighted the importance of the above nutrients for bone health and concluded that dairy foods are excellent sources for proper bone status, and that it is challenging to reach the recommended calcium intake without dairy products. Non-dairy alternatives for calcium include fortified plant-based milks, leafy green vegetables, canned fish with bones, almonds, and fortified cereals.

8.5 The Low-FODMAP Diet

Visceral hypersensitivity is present in at least half of patients with irritable bowel syndrome, and this group requires not only restriction of lactose intake but also a low-FODMAP diet to improve gastrointestinal complaints. The long-term effects of a dairy-free, low-FODMAP diet on nutritional health and the fecal microbiome are not well defined. Lactose is classified as a fermentable disaccharide under the FODMAP framework, and restriction may benefit individuals who have both lactose intolerance and IBS, though prolonged restriction carries nutritional risks.

8.6 Gut Microbiome Modulation Through Diet

Recent work highlights that lactose intolerance symptoms reflect both lactase nonpersistence (malabsorption) and host sensitivity, with inter-individual variability shaped by diet, genetics, and the gut microbiome. Undigested lactose may act as a beneficial prebiotic, fostering a healthier gut microbiome. This observation underpins the rationale for GOS supplementation as a microbiome-modulating strategy (see Section 7.4). Certain intestinal microorganisms, including Lactobacillus and Bifidobacterium, reduce the lactose concentration through their β-galactosidase activity. Altering the gut microbiota could be a long-term strategy to manage lactose intolerance.

8.7 Bone Health Monitoring

Long-term complications are unlikely when nutritional requirements, including adequate protein, caloric, calcium, and vitamin D intake, are maintained. In cross-sectional research, participants with self-reported lactose intolerance had lower intakes of milk and calcium than those without. The presence of self-reported lactose intolerance was associated with decreased bone mineral density (BMD) Z-score after adjustment for age, sex, body mass index, smoking, alcohol, vitamin D, and walking speed. This underscores the importance of dietary planning and, where necessary, supplementation for individuals who significantly restrict dairy.

References

• Misselwitz B, et al. "Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management." Gut. PMC6839734.
• Malik TF, Panuganti KK. "Lactose Intolerance." StatPearls. NCBI Bookshelf NBK532285.
• InformedHealth.org. "Overview: Lactose intolerance." NCBI/NIH NBK310267.
• Swagerty DL Jr, et al. "Lactose intolerance: pathophysiology, clinical symptoms, diagnosis and treatment." PubMed PMID 19388523.
• Deng Y, et al. "Lactose Intolerance." PubMed PMID 30335318.
• Misselwitz B, et al. "Lactose malabsorption and intolerance." PMC4040760.
• Kuokkanen M, et al. "Congenital Lactase Deficiency: Mutations, Functional and Biochemical Implications, and Future Perspectives." PMC6412902.
• Heyman MB. "Lactose Intolerance in Infants, Children, and Adolescents." Pediatrics. AAP.
• Crimarco A, et al. "Lactose Intolerance and Bone Health: The Challenge of Ensuring Adequate Calcium Intake." Nutrients. PMC6521087.
• Facioni MS, et al. "Nutritional management of lactose intolerance: the importance of diet and food labelling." PMC7318541.
• Storhaug CL, et al. "Lactose Intolerance in Adults: Biological Mechanism and Dietary Management." PMC4586575.
• Aguilera G, et al. "Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications." PMC12995986.
• Oak SJ, Jha R. "The effects of probiotics in lactose intolerance: A systematic review." PubMed PMID 29425071.
• Levri KM, et al. "Do probiotics reduce adult lactose intolerance? A systematic review." PubMed PMID 16009090.
• Oliveira GL, et al. "The use of probiotics and prebiotics can enable the ingestion of dairy products by lactose intolerant individuals." PubMed PMID 36308983.
• Leis R, et al. "Effects of Prebiotic and Probiotic Supplementation on Lactase Deficiency and Lactose Intolerance: A Systematic Review of Controlled Trials." PMC7284493.
• Savaiano DA. "Lactose digestion from yogurt: mechanism and relevance." Am J Clin Nutr. PubMed PMID 24695892.
• Wastyk HC, et al. "Yogurt, cultured fermented milk, and health: a systematic review." PMC8579104.
• Dahl WJ, et al. "Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients." PMC7231374.
• Savaiano DA, et al. "Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial." Nutrition Journal.
• Davis LMG, et al. "Prebiotics for Lactose Intolerance: Variability in Galacto-Oligosaccharide Utilization by Intestinal Lactobacillus rhamnosus." PMC6213946.
• Chumpitazi BP, et al. "Review article: The physiologic effects and safety of Peppermint Oil and its efficacy in irritable bowel syndrome and other functional disorders." PMC5814329.
• Alammar N, et al. "The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data." PMC6337770.
• Khanna R, et al. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." PubMed PMID 24100754.
• Nikkhah Bodagh M, et al. "Ginger in gastrointestinal disorders: A systematic review of clinical trials." PMC6341159.
• Brandao Gois MF, et al. "Role of the gut microbiome in mediating lactose intolerance symptoms." PMC8666824.
• Kato R, et al. "Self-reported lactose intolerance is inversely associated with calcium intake and bone mineral density." PMC12681473.